FDA: When it Comes to 3D Printing, the Future is Already Here
Are You Ready for the Precision Medicine Revolution?

An FDAnews FREE Webinar • Sponsored by  Dassault Systèmes
Thursday, Sept. 28, 2017 • 1:30 p.m. - 2:30 p.m. EDT

According to the FDA, when it comes to 3D printing, you might say that the future is already here. Due to its versatility, the agency is evaluating the application of 3D printing in devices, drugs and biologics.

3D Printing, Simulation and Digital Twin are at the forefront of the Precision Medicine Revolution. Using these technologies, Life Sciences companies are accelerating the delivery of next generation products that are personalized, more precise and higher quality than ever before, resulting in improved patient outcomes.

Hear the industry perspective from Thomas Marchand, Co-Founder & CEO of BIOMODEX, an innovative MedTech company, about how they are pioneering 3D Printing, Simulation and Digital Twin technologies to assist surgeons in planning and preparation for complex interventional procedures with the use of 3D printed replicas of the patient’s anatomy.

Get the physician’s perspective from Dr. Jenny Chen, a trained neuroradiologist and founder/CEO of 3DHEALS. Dr. Chen will share her perspectives on fostering a collaborative and innovative 3D printing ecosystem within the global healthcare arena.

In addition, Stavros Stefanis, leader in Deloitte’s Product Development practice, will share insights on the use of 3D printing across different phases of the product development lifecycle. He will also discuss strategies to successfully integrate 3D printing into product development and manufacturing.

By bridging the gap between the digital and the physical environments innovative companies are accelerating the delivery of higher quality device and therapeutic healthcare solutions.

In this webinar, moderated by Axendia’s Daniel Matlis, you will learn:

  • FDA’s expectations and guidance on these technologies
  • How simulation and 3D models of human cells and organs could be bio-printed to accelerate clinical trials to support the Precision Medicine revolution
  • How 3D Printing can enhance quality, innovation and improve patient outcomes
  • How 3D Printing can result in shorter lead-times and better user (patient or physician) experience
  • How to leverage these technologies to deliver smart and connected personalized products
  • How 3D printing enables and creates market differentiation and opens non-traditional business areas

Who Will Benefit

  • Executive Management
  • R&D
  • Product Design and Development
  • Clinical
  • Regulatory affairs
  • Quality assurance
  • Product Lifecycle managers
  • Manufacturing management
  • Project leaders
  • Risk managers
  • Metrics data managers
  • IT professionals

Sign Up for FREE Below

Meet Your Presenters


Thomas Marchand

Co-Founder & CEO

Thomas Marchand is a French entrepreneur who graduated from ESSEC Business School. He founded BIOMODEX in 2015 with Sidarth Radjou (Mechanical Engineer from Centrale Paris). This Medtech start-up develops 3d printed surgical simulators from CT scan for surgery planning and is part of the 3d Experience Lab, the startup accelerator driven by Dassault Systems.


Jenny Chen M.D.

Founder and CEO

Jenny is trained as a neuroradiologist and the founder and CEO of 3DHEALS, a company focusing on curating healthcare 3D printing ecosystem. Her main interests include medical education, 3D printing in the healthcare sector, and artificial intelligence. She is also a current adjunct clinical faculty in the radiology department at Stanford Healthcare.


Stavros Stefanis, PhD

Deloitte’s Product Development Practice

Stavros Stefanis is a leader in Deloitte’s Product Development practice and has 20 years of experience across many industries, with a primary focus on Innovation, Product Development and Supply Chain Transformation. Stavros has led numerous global transformation projects from strategy development through deployment, helping clients realize more than $1B dollars in directly measurable value.


Daniel R. Matlis (Moderator)

Founder and President

Daniel R. Matlis is Founder and President of Axendia, an analyst firm providing trusted advice to Life-Science and Healthcare Executives on Business, Technology and Regulatory matters. Dan has over 25 years of experience in the Industry spanning the entire value chain. He is an active member in FDA’s Case for Quality Initiative and has presented Axendia’s research findings to industry executives and the FDA.